Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

Rhea-AI Summary

Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT.

Media and investors may access the live audio webcast at www.knowlabs.co/investors, beginning at 1:15 pm PT. Questions to the Company’s management team can be submitted through the webcast portal during the meeting. The webcast will also be available for replay at the company’s website.

For more information on Know Labs and its progress in developing the first FDA-cleared non-invasive blood glucose monitoring device, visit www.knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211798532/en/

For Know Labs Media Inquiries Contact:

Matter Health

Abby Mayo

Knowlabs@matternow.com

Ph. (617) 272-0592



Know Labs, Inc. Contact:

Jordyn Hujar

jordyn@knowlabs.co

Ph. (206) 629-6414

Source: Know Labs, Inc.

FAQ

When will Know Labs, Inc. host a webcast to review its fiscal year results?

Know Labs, Inc. will host a webcast to review its fiscal year results on December 19, 2023, beginning at 1:30 pm PT.

What is the ticker symbol for Know Labs, Inc. on NYSE American?

The ticker symbol for Know Labs, Inc. on NYSE American is KNW.

What is Know Labs, Inc.'s focus as a company?

Know Labs, Inc. is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.

Where can media and investors access the live audio webcast?

Media and investors may access the live audio webcast at www.knowlabs.co/investors, beginning at 1:15 pm PT.

What progress has Know Labs, Inc. made in developing the non-invasive blood glucose monitoring device?

Know Labs, Inc. is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.

How can questions be submitted to Know Labs, Inc.'s management team during the webcast?

Questions to the Company’s management team can be submitted through the webcast portal during the meeting.